Neuland Laboratories Ltd
Neuland Laboratories Ltd (NEULANDLAB) last traded at ₹22,974, a market capitalisation of ₹29,475 crore, on a P/E of 59.2. Over the past 52 weeks the stock has ranged between ₹11,500 and ₹23,899. Neuland Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹642 crore and net profit of ₹148 crore. Figures are as of 25 Aug 2026 and are not real time.
Neuland Laboratories Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Neuland Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹642 cr, up 119.1% from ₹293 cr a year earlier. Net profit was ₹148 cr, up 957.1% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 311 | 398 | 328 | 293 | 514 | 440 | 776 | 642 |
| Expenses | 249 | 311 | 277 | 258 | 359 | 363 | 469 | 419 |
| Operating profit | 62 | 87 | 51 | 34 | 156 | 77 | 307 | 223 |
| OPM % | 20% | 22% | 16% | 12% | 30% | 18% | 40% | 35% |
| Other income | 4 | 60 | 7 | 8 | 2 | 8 | 12 | 8 |
| Interest | 1 | 2 | 2 | 5 | 5 | 7 | 7 | 7 |
| Depreciation | 16 | 16 | 17 | 20 | 23 | 24 | 25 | 27 |
| Profit before tax | 49 | 128 | 39 | 18 | 129 | 54 | 287 | 198 |
| Tax % | 34% | 20% | 29% | 21% | 25% | 26% | 26% | 25% |
| Net profit | 33 | 102 | 28 | 14 | 97 | 41 | 213 | 148 |
| EPS (₹) | 25.60 | 79.18 | 21.68 | 10.83 | 75.49 | 31.62 | 165.76 | 115.10 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Neuland Laboratories Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 937 | 951 | 1,191 | 1,559 | 1,477 | 2,023 | 2,372 |
| Operating profit | 147 | 144 | 273 | 463 | 331 | 580 | 763 |
| OPM % | 16% | 15% | 23% | 30% | 22% | 29% | 32% |
| Net profit | 81 | 64 | 164 | 300 | 260 | 364 | 498 |
| EPS (₹) | 62.85 | 49.74 | 127.45 | 233.89 | 202.74 | 283.71 | 387.97 |
TTM is the trailing twelve months to the most recent quarter.
Neuland Laboratories Ltd growth and returns
- 10 Years
- 15%
- 5 Years
- 17%
- 3 Years
- 19%
- TTM
- 78%
- 10 Years
- 29%
- 5 Years
- 39%
- 3 Years
- 30%
- TTM
- 278%
- 10 Years
- 36%
- 5 Years
- 70%
- 3 Years
- 80%
- 1 Year
- 69%
- 10 Years
- 14%
- 5 Years
- 18%
- 3 Years
- 20%
- Last Year
- 21%
Neuland Laboratories Ltd shareholding pattern
Promoters held 32.62% at Jun 2026, broadly unchanged since Jun 2025. FIIs 21.08% and DIIs 16.52%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 32.64% | 32.68% | 32.67% | 32.67% | 32.64% | 32.63% | 32.63% | 32.62% |
| FIIs | 26.46% | 23.86% | 22.12% | 21.69% | 20.60% | 20.90% | 20.46% | 21.08% |
| DIIs | 6.38% | 9.09% | 10.97% | 11.57% | 13.55% | 14.72% | 15.84% | 16.52% |
| Government | 0.40% | 0.40% | 0.40% | 0.40% | 0.40% | 0.00% | 0.00% | 0.00% |
| Public | 34.12% | 33.96% | 33.85% | 33.67% | 32.80% | 31.76% | 31.08% | 29.79% |
| No. of shareholders | 34,567 | 39,315 | 39,333 | 42,419 | 44,393 | 46,187 | 46,304 | 44,340 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Neuland Laboratories Ltd corporate filings
- Announcement under Regulation 30 (LODR) - Credit RatingCompany Updatemedium impact
Cruxal's analysis: Neuland Laboratories Limited has announced that CRISIL Ratings has reaffirmed its…
Read the full analysis - Copy of Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Neuland Laboratories Ltd has published its financial results in newspapers as per…
Read the full analysis - The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Malabar India Fund LtdInsider Trading / SASTmedium impact
Cruxal's analysis: Malabar India Fund Limited has disclosed a reduction in its shareholding in Neuland…
Read the full analysis - Intimation regarding completion of US FDA InspectionCompany Updatelow impact
Cruxal's analysis: Neuland Laboratories has formally intimated the completion of a US FDA inspection at its…
Read the full analysis - Transcript of the Earnings Call conducted on August 5, 2026Company Updatehigh impact
Cruxal's analysis: Neuland Laboratories Limited reported Q1 FY27 total income of 650.1 crore, up 16.3% YoY…
Read the full analysis - Intimation about Schedule of Analyst / Institutional Investor Meeting on August 12, 2026Company Updatelow impact
Cruxal's analysis: Neuland Laboratories has announced a scheduled meeting with analysts and institutional…
Read the full analysis - Copy of Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Neuland Laboratories Ltd has published a notice in newspapers in compliance with…
Read the full analysis - Disclosure under Regulation 30 of SEBI Listing Regulations - Enhancement of manufacturing capacityCompany Updatemedium impact
Cruxal's analysis: Neuland Laboratories has disclosed an enhancement of its manufacturing capacity under…
Read the full analysis - Disclosure under Regulation 30 of SEBI Listing Regulations - Execution of deed of Corporate GuaranteeCompany Updatelow impact
Cruxal's analysis: Neuland Laboratories has executed a deed of corporate guarantee in compliance with…
Read the full analysis - Investor Presentation on the Financial Results of the Company for the quarter ended June 30, 2026Company Updatehigh impact
Cruxal's analysis: Neuland Laboratories Limited delivered robust Q1 FY27 results, reporting a total income…
Read the full analysis - Press Release on the Financial Results of the Company for the quarter ended June 30, 2026Company Updatehigh impact
Cruxal's analysis: Neuland Laboratories Limited delivered robust Q1 FY27 financial results, reporting total…
Read the full analysis - Unaudited Financial Results of the Company for the quarter ended June 30, 2026Resulthigh impact
Cruxal's analysis: Neuland Laboratories Limited reported robust Q1 FY27 consolidated revenue of 641.58 crore…
Read the full analysis - Voting Results, Scrutinizer Report and proceeding of 42nd Annual General Meeting held on August 4, 2026AGM/EGMhigh impact
Cruxal's analysis: Neuland Laboratories Limited's 42nd Annual General Meeting held on August 4, 2026…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Neuland Laboratories Ltd
Cruxal reads every Neuland Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.